

Author: Hack Sabine Nash Lawrence T
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.3, Iss.5, 2002-05, pp. : 555-571
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
As the recognition of paediatric and adolescent anxiety disorders improves, so does the number of recommended treatments. Newer medications (chiefly serotonergic antidepressants) have emerged as the pharmacological treatment of choice and have largely replaced benzodiazepines and tricyclic antidepressants (TCAs) for these disorders. This review will focus on placebo-controlled and open-label studies concerning the treatment of anxiety in children and adolescents, comparing data from newer antidepressant medications (plus buspirone) with data on TCAs and benzodiazepines in this population. There are few randomised, placebo-controlled trials of medications for anxiety in children and adolescents, with most data coming from open-label trials and case series. Moreover, there are no studies comparing pharmacological versus behavioural treatments. Most recent data concerning the efficacy of selective serotonin reuptake inhibitors suggests that these agents will be effective and safe in the treatment of paediatric anxiety disorders. The potential side effect profiles of these newer agents also makes them an attractive first choice for anxiety when compared to the benzodiazepines or TCAs, each of which poses its own potentially serious adverse effects. More research is needed in the area of psychopharmacological treatments for paediatric and adolescent anxiety, not only to substantiate the current beliefs that serotonergic agents are effective and safe but to pinpoint the factors that might predict responses to particular agents or classes of medications. Future investigations should focus on treatments which have already proven effective for adult anxiety disorders (both medications and psychotherapies), given the apparent links between paediatric and adult anxiety disorders.
Related content


Treatment of Anxiety Disorders in Children and Adolescents
Child and Adolescent Psychopharmacology News, Vol. 19, Iss. 5, 2014-10 ,pp. :


Pharmacological treatment of anxiety disorders: an overview
By Leacute pine J.P. Pelissolo A.
European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. :


Pharmacological Treatment of Depression in Children and Adolescents
Pediatric Drugs, Vol. 1, Iss. 3, 1999-07 ,pp. :


Room for Improvement in the Pharmacological Treatment of Anxiety Disorders
Current Pharmaceutical Design, Vol. 14, Iss. 33, 2008-11 ,pp. :


Spotlight on Fluvoxamine in Anxiety Disorders in Children and Adolescents
CNS Drugs, Vol. 16, Iss. 2, 2002-01 ,pp. :